Understanding the French Pharmaceutical Landscape As foreign pharmaceutical companies look to expand their reach into the European market, France stands out as a key player. Known for its robust healthcare system and a population keen on high-quality medical care, France offers a promising avenue for growth. However, navigating the regulatory environment can be challenging. A…

The Service Médical Rendu (SMR), or Medical Service Rendered, is a fundamental concept in the French healthcare system, particularly in the context of pharmaceuticals. It is a measure used to evaluate the therapeutic benefit of a medication, which plays a pivotal role in determining its reimbursement by the National Health Insurance (NHI). What is SMR?…

France’s healthcare system is renowned for its efficiency and effectiveness, providing high-quality medical care to its citizens. This success is largely attributed to the various government bodies that oversee different aspects of healthcare. Understanding the roles and connections of these bodies is crucial for anyone looking to engage with the French healthcare sector. Let’s take…

In the heart of France’s innovative healthcare landscape, the Early Access Program (EAP), locally known as “Accès Précoce” (formerly “Autorisation Temporaire d’Utilisation” or ATU), stands as a beacon of hope. This remarkable program bridges the gap between urgent patient needs and medical innovation, offering a lifeline to those facing serious or rare diseases with no…

The pharmaceutical industry is a vast landscape of innovation, regulatory standards, and international processes. As US-based pharmaceutical companies expand their operations and look to tap into the European market, it’s imperative to understand the regulatory environment. One of the most pivotal regulatory pathways for gaining market access in Europe is the Centralised Procedure. Here’s a…

Have a look at our infographic on how the French Pharmaceutical market works, the size and some other valuable information

Are you considering venturing into the realm of off-patent pharmaceutical products? This market segment offers immense opportunities for growth and diversification of your product portfolio. However, navigating the complexities from initial discussions to the final stages of acquisition and transfer can be daunting. That’s where our expertise comes into play. Our Comprehensive Approach At our…

What affects the supply of medicine in the Pharmaceutical Industry? One of the main reasons that prescription drug costs make headlines is because of the actors in the supply chain. This study aims to investigate the reasons for the lack of medicines and their effects on the supply of medicines. We could learn more about…

In the dynamic world of healthcare, understanding the patient journey—often termed as ‘care flow’—is a crucial aspect that pharmaceutical companies cannot afford to overlook. This journey encompasses a comprehensive visual map of care events, charting the course from the onset of symptoms to the achievement of a cure. Traditionally, the focus within the pharmaceutical industry…

The retail pharmacy landscape in France presents a fascinating study in uniqueness, distinctly different from its European counterparts. This article delves into the nuances of this market, highlighting what sets French retail pharmacies apart. A Market of Singular Ownership In a striking contrast to many European countries, France does not have pharmacy chains. This means…